Amgen Inc. $AMGN Shares Bought by MML Investors Services LLC

MML Investors Services LLC raised its position in Amgen Inc. (NASDAQ:AMGN) by 5.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 205,275 shares of the medical research company’s stock after acquiring an additional 10,466 shares during the quarter. MML Investors Services LLC’s holdings in Amgen were worth $67,189,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the company. Mosaic Financial Group LLC acquired a new stake in shares of Amgen in the fourth quarter valued at approximately $253,000. Mariner LLC increased its stake in shares of Amgen by 1.7% during the fourth quarter. Mariner LLC now owns 1,071,393 shares of the medical research company’s stock valued at $350,682,000 after acquiring an additional 18,222 shares during the period. Motiv8 Investments LLC acquired a new position in shares of Amgen during the fourth quarter valued at approximately $65,000. Evernest Financial Advisors LLC increased its stake in shares of Amgen by 7.0% during the fourth quarter. Evernest Financial Advisors LLC now owns 3,604 shares of the medical research company’s stock valued at $1,180,000 after acquiring an additional 236 shares during the period. Finally, Focus Partners Wealth increased its stake in shares of Amgen by 60.7% during the fourth quarter. Focus Partners Wealth now owns 366,355 shares of the medical research company’s stock valued at $113,525,000 after acquiring an additional 138,334 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Piper Sandler reiterated an “overweight” rating on shares of Amgen in a research note on Friday. Jefferies Financial Group assumed coverage on shares of Amgen in a report on Tuesday, March 10th. They set a “hold” rating and a $350.00 target price for the company. Guggenheim decreased their price objective on shares of Amgen from $351.00 to $340.00 and set a “neutral” rating for the company in a research note on Monday, May 4th. The Goldman Sachs Group set a $389.00 price objective on shares of Amgen in a research note on Friday, June 5th. Finally, Canaccord Genuity Group assumed coverage on shares of Amgen in a research note on Monday, April 20th. They issued a “hold” rating and a $366.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $354.12.

Insider Activity

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 0.85% of the stock is owned by company insiders.

Amgen Trading Down 1.3%

Amgen stock opened at $350.53 on Tuesday. The company has a 50 day moving average price of $341.03 and a 200 day moving average price of $345.86. Amgen Inc. has a 52 week low of $267.83 and a 52 week high of $391.29. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The firm has a market capitalization of $189.18 billion, a price-to-earnings ratio of 24.39, a P/E/G ratio of 3.56 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The firm had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company’s revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the business posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Research analysts forecast that Amgen Inc. will post 22.38 EPS for the current year.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.